Inactive Instrument

News AntriaBio Inc OTC Bulletin Board

Equities

US0372301095

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 18	JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	MT
Mar. 06	Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	Apr. 23	GL
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	Apr. 23	AQ
JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	Apr. 18	MT
REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358 FOR TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA	Mar. 07	AQ
Rezolute : Corporate Presentation – March 2024	Mar. 06	PU
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	Mar. 06	GL
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	Mar. 06	AQ
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	Mar. 06	CI
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update	Feb. 13	GL
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	Jan. 24	GL
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	Jan. 24	AQ
Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer	Jan. 24	CI
REZOLUTE RECEIVES INNOVATION PASSPORT DESIGNATION FROM THE U.K. INNOVATIVE LICENSING AND ACCESS PATHWAY STEERING GROUP FOR RZ358	Jan. 24	AQ
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	Jan. 23	GL
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	Jan. 23	CI
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism	Dec. 14	GL
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)	Dec. 13	GL
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	Dec. 13	CI
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"	Nov. 24	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AntriaBio Inc OTC Bulletin Board

Equities

US0372301095

Summary

Filters